logo
Plus   Neg
Share
Email

Micro Focus Suspends Final Dividend - Quick Facts

Micro Focus International plc. (MCRO.L) said that its board is no longer recommending a final dividend for the year ended 31 October 2019 and therefore it plans to withdraw resolution relating to the approval of a proposed final dividend of 58.33 cents per ordinary share at its forthcoming Annual General Meeting. The move is due to the current increased macro uncertainty, which has been impacted by the global spread of COVID-19.

The company said it will consider paying a second interim dividend in respect of the year ended 31 October 2019 once there is some visibility on the effects of the COVID-19 on the company's business.

The company's Annual General Meeting will be held on 25 March 2020.

In view of the ongoing COVID-19 pandemic, Micro Focus is asking shareholders to appoint the Chairman as their proxy -- either electronically or by post-- with their voting instructions rather than attend the AGM in person.

The deadline for voting is on 23 March 2020 for shareholders and on 18 March 2020 for ADR shareholders.

For comments and feedback contact: editorial@rttnews.com

Business News

Editors Pick
Avalon Furniture is recalling about 9,500 units of Cottage Town Bedroom Furniture collection sold through Rooms To Go due to violation of federal lead paint ban, the U.S. Consumer Product Safety Commission said in a statement. According to the agency, the base coat paint used on pieces within the furniture collection contains levels of lead that exceed the federal lead paint standard. Sanofi and Regeneron Pharmaceuticals, Inc. announced that the U.S. Phase 3 trial of arthritis drug Kevzara (sarilumab) 400 mg in COVID-19 patients requiring mechanical ventilation did not meet its primary and key secondary endpoints. In the trial, Kevzara was added to best supportive care compared to best supportive care alone (placebo). The companies have stopped the U.S. trial. Shares of Moderna Inc. (MRNA) slipped over 5% on Thursday after a report claimed that the biotechnology company's late-stage trial for a coronavirus vaccine will be delayed. Moderna is developing mRNA-1273 in collaboration with the National Institute of Allergy and Infectious Diseases (NIAID). The...
RELATED NEWS
Follow RTT